logo
23andMe Bankruptcy Affects Marginalized People Who Didn't Share DNA

23andMe Bankruptcy Affects Marginalized People Who Didn't Share DNA

Forbes08-04-2025
There is no rugged individualism in our DNA. Your sequenced DNA can reveal sensitive information ... More about your DNA relatives and people like you.
Sequencing DNA can be empowering. But the recent 23andMe bankruptcy announcement has thrust privacy into the spotlight. Over 15 million people sent their spit to 23andMe, and the DNA they shared may have exposed people who didn't to privacy risks – relatives, perhaps, or people with similar traits or demographic characteristics. As customers with buyer's remorse rush to delete their genetic information (as I've reported here), millions more who don't have an account but whose DNA is linked to those who do have no such recourse. This is especially troubling for people from vulnerable or marginalized groups. The bankruptcy court could appoint a consumer privacy ombudsman to address these concerns, but it seems unlikely.
'I've always questioned how we use individual consent as the lawful basis/condition for the processing of sensitive personal information where there is such a highly asymmetric power dynamic,' writes Samantha Simms in a recent LinkedIn post. The digital lawyer and coach tells me she's particularly concerned about the high numbers of people with Caribbean, African American and Latin American backgrounds who flocked to take the tests 'because the lure of these services is profoundly emotional.'
Once sequenced, DNA can tell you where you came from, but this blueprint of life can also tell you what lies ahead. It can act as an early warning system for disease risk and a roadmap for personalized medicine. So it's no surprise that direct-to-consumer genetic testing is so popular.
Sequenced DNA is also popular with biomedical researchers and pharmaceutical companies, who can use it to link genetic markers to diseases or traits and find cures. For example, researchers have discovered that mutations in the BRCA-1 and BRCA-2 genes signal higher risk for certain cancers like breast cancer. People can now be screened for cancer risk and plan early interventions. With DTC genetic testing, they don't need to wait for a doctor to order tests.
Yet bioethicists, privacy experts and national security experts warn that genetic information can also be misused in dangerous ways. We can't change our DNA if it falls into the wrong hands, unlike other identifiers like a social security number. Greshake Tzovaras, founder of the now-closed OpenSNP project, told 404 Media why he decided to shut down the genetic database he'd created to democratize genomic research. He's seen how genetic databases intended for biomedical research have largely been re-purposed for law enforcement. He cites 'a rise in far-right and other authoritarian governments' as a key driver for deleting the data, which he fears could be used to target individuals or create pseudo-scientific justifications to vilify vulnerable groups.
'Thinking about gender representation, minorities, sexual orientation—23andMe has been working on the whole 'gay gene' thing, it's conceivable that this would at some point in the future become an issue.'
The U.S. Department of Justice has issued a final rule prohibiting the bulk transfer or sale of genomic data to 'countries of concern' like China. The rule extends to the sale of de-identified genomic data because it can be matched with other information to re-identify individuals or used to attack an identifiable population. The risks are significant: the same data used to offer personalized medical treatment could also be weaponized to hyper-target pathogens or bioweapons. But the rule doesn't prevent 23andMe from selling genetic data to buyers in other countries not listed as 'countries of concern.' Nor does it prevent domestic actors from misusing genetic data, as I've discussed here.
Simms does a lot of ancestral research, but she can only trace her story back to 1784. Like many in her community, she longs to understand her history pre-1600s. 'Coming from a people displaced by over 300 years of genocidal chattel slavery, I cannot provide any more precise details of my African ancestry without the aid of a direct-to-consumer DNA testing company, such as 23andMe,' writes Simms on LinkedIn.
'We often carry the ache of a tree without roots. With few photographs, no clear family records, and little oral history preserved, DNA testing offers, albeit partial, answers to an individual's story. The desire to know where we come from is so fundamental that it often outweighs what is seen as the more abstract risks to privacy.'
Despite this, Simms eventually decided against using a DTC genetic testing service over privacy risks and fears about how this data could be used against her community. Breaches, lack of transparency and control, and the possibility of unchecked sharing, data enrichment and profiling by data brokers were top of mind. Now, with the Trump administration's aggressive anti-DEI measures and health secretary RFK Jr. making race-based assertions regarding Black people and COVID, Simms is worried about U.S. government access to genetic data.
Dr. Krystal Tsosie, an Indigenous geneticist-bioethicist and assistant professor at Arizona State University tells me that DTC genetic testing exposes Indigenous communities to unique group privacy risks. Because they tend to be small with shorter generational gaps and larger families, both individuals and tribal communities are re-identifiable. She worries about the stigmatizing effects of genomic profiling; the use of genomic data for research never agreed by those communities; and the loss of Indigenous Data Sovereignty.
Historical misuse of Indigenous data by researchers has caused some tribes to issue moratoria against sharing their genetic data with researchers. In addition, concerns over community privacy have spurred tribal leaders to discourage their members from using DTC genetic testing services. Researchers sometimes fill these gaps using data from other communities as proxies, raising serious accuracy and data quality concerns.
Dr. Tsosie notes that colonially displaced descendants of Native Americans hoping to re-connect with those communities feel compelled to turn to DNA testing for answers. But this reifies it as a biological construct and raises concerns around false claims to Indigeneity. 'We construct belonging and citizenship in ways that do not consider these genetic ancestry tests. So it's not just a matter of what you claim, but it's a matter of who claims you,' says Kim Tallbear in an interview with CBC. Tallbear is Dakota, a professor in the Faculty of Native Studies at the University of Alberta and author of Native American DNA; Tribal Belonging and the False Promise of Genetic Science. She emphasizes that sharing genetic material doesn't constitute lived experience in community, or shared values, beliefs and cultural practices.
It's one thing to accept privacy risks for yourself. When your choices impact others, the risks are amplified. Simms wasn't ready to take a leap of faith with 23andMe, despite its privacy assertions. She feels vindicated. 'Large-scale data breaches, attempts to purchase data by the CEO post-bankruptcy, and an inability to handle deletion requests are not in line with a company that honoured its role to emotionally vulnerable consumers,' she says of 23andMe. 'There is no perfect fix for this imbalance.' Until there is, the safest approach may be not to share at all.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Beating Cancer With the Heart: One Professor's Mindset Helped Him Stay Healthy for 15 Years
Beating Cancer With the Heart: One Professor's Mindset Helped Him Stay Healthy for 15 Years

Epoch Times

time3 hours ago

  • Epoch Times

Beating Cancer With the Heart: One Professor's Mindset Helped Him Stay Healthy for 15 Years

A 7.5-inch tumor, lung metastasis, and multiple rounds of treatment—Han Bo-Cheng, an honorary professor at Taipei Medical University, overcame all odds to defeat liver cancer. Fifteen years later, he remains cancer-free and attributes his recovery not only to medicine but to one powerful force: emotional healing. His story offers hope and insight for those facing cancer or any life-altering crisis. Healing from the Inside Out: A Cancer Survivor's Journey When you are diagnosed with cancer, how you face the illness and navigate treatment becomes a major concern for both you and your loved ones. For Han, the turning point wasn't just medical—it was emotional. In 2008, Han was diagnosed with liver cancer and discovered a massive 7.5-inch, 4.4-pound tumor. After undergoing surgery to remove two-thirds of his liver, the cancer later spread to his lungs. He endured 25 chemotherapy sessions, 12 rounds of radiation, and targeted drug therapy. When the cancer recurred three years later, he required another surgery. Since then, Han has remained cancer-free. Not only has he regained his health, but he also appears younger than his age—something he credits to a complete transformation in mindset. Emotional Healing: The Missing Piece in Cancer Recovery Han believes a crucial part of healing lies in addressing emotions. 'I am the root of all problems, and love is the answer to all of them,' Han said in an interview with NTDTV's 'Health 1+1' program—a central realization during his recovery.

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Miami Herald

time4 hours ago

  • Miami Herald

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

USA Today

time4 hours ago

  • USA Today

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ('MIRA' or the 'Company'), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. 'These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential,' said Erez Aminov, Chairman and CEO of MIRA. 'We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain.' Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline levels. Its analgesic effect was equivalent to morphine, the standard opioid comparator in the study. No sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. 'Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs,' said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. 'Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards.' Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. 'With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated,' added Aminov. 'We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline.' Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. 'We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation,' said Aminov. 'This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth.' Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Helga Moya info@ (786) 432-9792 SOURCE: MIRA Pharmaceuticals View the original press release on ACCESS Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store